Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527903 | 0.92 | MAPT (0.37) | MAPTNPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL16632631 | 0.82 | CA1 (0.39) | MAPTALDH1A1POLB | |
| SCHEMBL9894437 | 0.79 | MAPT (0.50) | G6PDMAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL9893973 | 0.79 | NPC1 (0.59) | G6PDMAPTMAPK1NPC1RAB9A | |
| SCHEMBL29288019 | 0.77 | MAPT (0.48) | G6PDMAPTALDH1A1TYRO3L3MBTL1 | |
| SCHEMBL30672492 | 0.77 | MAPT (0.48) | G6PDMAPTALDH1A1TYRO3L3MBTL1 | |
| SCHEMBL9895322 | 0.77 | MAPT (0.35) | MAPTALDH1A1KMT2A | |
| SCHEMBL1372778 | 0.76 | MET (0.44) | — | |
| SCHEMBL455086 | 0.76 | MAPT (0.42) | G6PDMAPTALDH1A1TYRO3MEN1 | |
| SCHEMBL9894267 | 0.75 | ALDH1A1 (0.40) | MAPTRAB9AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630928-B2 | Intermediates to prepare herbicidal pyrimidone derivatives | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2475654-B1 | HERBICIDAL PYRIMIDONE DERIVATIVES | DU PONT (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20160024020-A1 | INTERMEDIATES TO PREPARE HERBICIDAL PYRIMIDONE DERIVATIVES | FMC CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-9187432-B2 | Intermediates to prepare herbicidal pyrimidone derivatives | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150105549-A1 | INTERMEDIATES TO PREPARE HERBICIDAL PYRIMIDONE DERIVATIVES | FMC CORPORATION | 2015-04-16 | — | — | US | disclosed |
| US-8952024-B2 | Herbicidal pyrimidone derivatives | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-20120149573-A1 | HERBICIDAL BUS-NITROGEN-CONTAINING OXO AND SULFONO HETEROCYCLES | FMC CORPORATION | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149573-A1 | HERBICIDAL BUS-NITROGEN-CONTAINING OXO AND SULFONO HETEROCYCLES | CBR3, CYP1B1, CBR1 | G6PD 1885/4885MAPT 4805/4885MAPK1 1709/4885 |
| US-20150105549-A1 | INTERMEDIATES TO PREPARE HERBICIDAL PYRIMIDONE DERIVATIVES | CBR3, CBR1, MSRB3 | G6PD 151/4885MAPT 4761/4885MAPK1 1973/4885 |
| US-20160024020-A1 | INTERMEDIATES TO PREPARE HERBICIDAL PYRIMIDONE DERIVATIVES | CBR3, CBR1, PNPO | G6PD 133/4885MAPT 4753/4885MAPK1 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.